Erratum: Atherogenic serum lipid profile is an independent predictor for gouty flares in patients with gouty arthropathy (Rheumatology (2009) vol. 48 (262-265) 10.1093/rheumatology/ken471);Atherogenic serum lipid profile is an independent predictor for gouty flares in patients with gouty arthropathy

Rheumatology

Volumn 48, Issue 3, 2009, Pages 262-265

  Mak, A ^a   Ho, R C M ^a   Tan, J Y S ^a   Teng, G G ^a   Lahiri, M ^a   Lateef, A ^a   Vasoo, S ^a   Boey, M L ^a   Koh, D R ^a,b   Feng, P H ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Atherogenic; Flares; Gout; High density lipoprotein cholesterol; Lipid profile

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; COLCHICINE; CORTICOSTEROID; CREATININE; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; URIC ACID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET RESTRICTION; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GOUT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; URIC ACID BLOOD LEVEL;

EID: 61349116937     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep114     Document Type: Erratum

References (32)

1. Annemans L, Spaepen E, Gaskin M et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6.
2. De Leonardis F, Govoni M, Colina M, Bruschi M, Trotta F. Elderly-onset gout: A review. Rheumatol Int 2007;28:1-6.
3. Choi HK, Curhan G. Gout: Epidemiology and lifestyle choices. Curr Opin Rheumatol 2005;17:341-5.
4. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-103.
5. Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57:816-21.
6. Eggebeen AT. Gout: An update. Am Fam Physician 2007;76:801-8.
7. Friedman JE, Dallal RM, Lord JL. Gouty attacks occur frequently in postoperative gastric bypass patients. Surg Obes Relat Dis 2008;4:11-3.
8. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: Analysis from managed care data. J Clin Rheumatol 2006;12:61-5.
9. Hunter DJ, York M, Chaisson CE, Woods R, Niu J, Zhang Y. Recent diuretic use and the risk of recurrent gout attacks: The online case-crossover gout study. J Rheumatol 2006;33:1341-5.
10. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology 2007;46:1441-4.
11. Rho YH, Choi SJ, Lee YH et al. The prevalence of metabolic syndrome in patients with gout: A multicenter study. J Korean Med Sci 2005;20:1029-33.
12. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007;3:443-9.
13. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003;10:63-71.
14. White D, Fayez S, Doube A. Atherogenic lipid profiles in rheumatoid arthritis. N Z Med J 2006;119:U2125.
15. Cabana VG, Gidding SS, Getz GS, Chapman J, Shulman ST. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 1997;42:651-5.
16. van Halm VP, van Denderen JC, Peters MJ et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1473-7.
17. Park YB, Choi HK, Kim MY et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: A prospective study. Am J Med 2002;113:188-93.
18. van Halm VP, Nielen MM, Nurmohamed MT et al. Lipids and inflammation: Serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184-8.
19. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
20. Zhang W, Doherty M, Pascual E et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
21. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353: 2450-61.
22. Lee YH, Choi SJ, Ji JD, Seo HS, Song GG. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000;19:324-5.
23. Gomaraschi M, Calabresi L, Rossoni G et al. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J Pharmacol Exp Ther 2008;324:776-83.
24. Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: The missing link between infection and chronic inflammation? Autoimmun Rev 2002;1:111-7.
25. Hyka N, Dayer JM, Modoux C et al. Apo AI inhibits the production of IL-1β and TNFα by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001;97:2381-9.
26. Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: Implications for therapy. Arthritis Rheum 2007;56:3183-8.
27. Akahoshi T, Murakami Y, Kitasato H. Recent advances in crystal-induced acute inflammation. Curr Opin Rheumatol 2007;19:146-50.
28. Chen CJ, Shi Y, Hearn A et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006;116:2262-71.
29. Van Lenten BJ, Reddy ST, Navab M, Fogelman AM. Understanding changes in high density lipoproteins during the acute phase response. Arterioscler Thromb Vasc Biol 2006;26:1687-8.
30. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
31. Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007;56:1384-96.
32. McMahon M, Grossman J, FitzGerald J et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9.